LBA63 Placebo-controlled, double-blinded phase Ⅲ study comparing dexamethasone on day 1 with dexamethasone on days 1 to 4, with combined neurokinin-1 receptor antagonist, palonosetron, and olanzapine in patients receiving cisplatin-containing highly emetogenic chemotherapy: SPARED trial

Kyoichi Shimomura ,C Katada,Yuna Inada ,Tai Yamaguchi ,Kazuhiko Mishima ,Tempei Miyaji ,Shuichi Nawata ,Ayako Tsuboya ,Naoki Izawa ,Nobuyuki Hida ,Kana Honda ,Katsuyosi Akiyama ,Mitsuru Sugawara ,Hiroko Minatogawa ,Hiroki Morita ,Hirotoshi Iihara ,Hitoshi Arioka ,Tomoe Mashiko ,Yoshiyuki Ohno ,T Nakajima

doi:10.1016/j.annonc.2021.08.2144

LBA63 Placebo-controlled, double-blinded phase Ⅲ study comparing dexamethasone on day 1 with dexamethasone on days 1 to 4, with combined neurokinin-1 receptor antagonist, palonosetron, and olanzapine in patients receiving cisplatin-containing highly emetogenic chemotherapy: SPARED trial

Kyoichi Shimomura , C Katada + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2021.08.2144

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2021
Citations: 4	License type: publisher-specific-oa

#Neurokinin-1 Receptor Antagonist #Palonosetron + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Olanzapine (OLZ) 5 mg combined with dexamethasone (DEX), neurokinin-1 receptor antagonist (NK1-RA), and palonosetron (PALO) has been established as the standard for patients (pts) receiving cisplatin (CDDP)-containing highly emetogenic chemotherapy (HEC). This study aimed to clarify the non-inferiority of DEX sparing when combined with NK1-RA, PALO, and OLZ in CDDP-containing HEC.

Full Text